Portfolio

Innovative Oncology therapies across multiple drug classes to improve patient lives

Small Molecule

Candidate Name

Class

Indication

Candidate Name

Class

Indication

Candidate Name

Class

Indication

Candidate name

EP0031

Indication

RET+ Solid Tumours

Phase 2

Candidate Name

Class

Indication

Nanoparticle

Candidate Name

Class

Indication

Candidate name

EP0057

Class

Nanoparticle - Drug Conjugate

Indication

Ovarian and Gastric Cancer

Phase 2